nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—DRD1—nerve—multiple sclerosis	0.0298	0.093	CbGeAlD
Phenylpropanolamine—SLC6A3—nerve—multiple sclerosis	0.024	0.0747	CbGeAlD
Phenylpropanolamine—SLC6A2—nerve—multiple sclerosis	0.0193	0.0603	CbGeAlD
Phenylpropanolamine—Liver injury—Fingolimod—multiple sclerosis	0.0192	0.0606	CcSEcCtD
Phenylpropanolamine—MAOA—nerve—multiple sclerosis	0.0178	0.0556	CbGeAlD
Phenylpropanolamine—ADRA2A—peripheral nervous system—multiple sclerosis	0.0175	0.0547	CbGeAlD
Phenylpropanolamine—Pseudoephedrine—IL2—multiple sclerosis	0.0134	0.557	CrCbGaD
Phenylpropanolamine—DRD1—brainstem—multiple sclerosis	0.0128	0.0399	CbGeAlD
Phenylpropanolamine—SLC6A3—brainstem—multiple sclerosis	0.0103	0.0321	CbGeAlD
Phenylpropanolamine—Liver injury—Azathioprine—multiple sclerosis	0.00887	0.0279	CcSEcCtD
Phenylpropanolamine—SLC6A2—brainstem—multiple sclerosis	0.0083	0.0259	CbGeAlD
Phenylpropanolamine—DRD1—midbrain—multiple sclerosis	0.00816	0.0254	CbGeAlD
Phenylpropanolamine—ADRA1A—brainstem—multiple sclerosis	0.00771	0.0241	CbGeAlD
Phenylpropanolamine—MAOA—brainstem—multiple sclerosis	0.00764	0.0238	CbGeAlD
Phenylpropanolamine—Hepatocellular injury—Azathioprine—multiple sclerosis	0.00746	0.0235	CcSEcCtD
Phenylpropanolamine—MAOA—retina—multiple sclerosis	0.00737	0.023	CbGeAlD
Phenylpropanolamine—DRD1—nervous system—multiple sclerosis	0.0067	0.0209	CbGeAlD
Phenylpropanolamine—Vision blurred—Fingolimod—multiple sclerosis	0.00667	0.021	CcSEcCtD
Phenylpropanolamine—SLC6A3—midbrain—multiple sclerosis	0.00655	0.0204	CbGeAlD
Phenylpropanolamine—DRD1—central nervous system—multiple sclerosis	0.00645	0.0201	CbGeAlD
Phenylpropanolamine—SLC6A3—spinal cord—multiple sclerosis	0.00639	0.02	CbGeAlD
Phenylpropanolamine—Ataxia—Cladribine—multiple sclerosis	0.00626	0.0197	CcSEcCtD
Phenylpropanolamine—Ephedrine—BCHE—multiple sclerosis	0.00616	0.256	CrCbGaD
Phenylpropanolamine—SLC6A2—medulla oblongata—multiple sclerosis	0.00578	0.018	CbGeAlD
Phenylpropanolamine—Hypotension—Fingolimod—multiple sclerosis	0.0054	0.017	CcSEcCtD
Phenylpropanolamine—SLC6A3—nervous system—multiple sclerosis	0.00539	0.0168	CbGeAlD
Phenylpropanolamine—MAOA—medulla oblongata—multiple sclerosis	0.00533	0.0166	CbGeAlD
Phenylpropanolamine—SLC6A3—central nervous system—multiple sclerosis	0.00519	0.0162	CbGeAlD
Phenylpropanolamine—Dyspnoea—Fingolimod—multiple sclerosis	0.00515	0.0162	CcSEcCtD
Phenylpropanolamine—DRD1—brain—multiple sclerosis	0.00512	0.016	CbGeAlD
Phenylpropanolamine—ADRB1—nervous system—multiple sclerosis	0.00511	0.0159	CbGeAlD
Phenylpropanolamine—SLC6A3—cerebellum—multiple sclerosis	0.00507	0.0158	CbGeAlD
Phenylpropanolamine—ADRB1—central nervous system—multiple sclerosis	0.00492	0.0154	CbGeAlD
Phenylpropanolamine—MAOA—midbrain—multiple sclerosis	0.00487	0.0152	CbGeAlD
Phenylpropanolamine—MAOA—spinal cord—multiple sclerosis	0.00475	0.0148	CbGeAlD
Phenylpropanolamine—Pseudoephedrine—TNF—multiple sclerosis	0.00453	0.188	CrCbGaD
Phenylpropanolamine—SLC6A2—nervous system—multiple sclerosis	0.00435	0.0136	CbGeAlD
Phenylpropanolamine—Euphoric mood—Prednisolone—multiple sclerosis	0.00425	0.0134	CcSEcCtD
Phenylpropanolamine—SLC6A2—central nervous system—multiple sclerosis	0.00418	0.0131	CbGeAlD
Phenylpropanolamine—SLC6A3—brain—multiple sclerosis	0.00412	0.0128	CbGeAlD
Phenylpropanolamine—Arrhythmia—Cladribine—multiple sclerosis	0.00412	0.013	CcSEcCtD
Phenylpropanolamine—ADRA2A—medulla oblongata—multiple sclerosis	0.00409	0.0128	CbGeAlD
Phenylpropanolamine—ADRA1A—nervous system—multiple sclerosis	0.00404	0.0126	CbGeAlD
Phenylpropanolamine—MAOA—nervous system—multiple sclerosis	0.004	0.0125	CbGeAlD
Phenylpropanolamine—Euphoric mood—Triamcinolone—multiple sclerosis	0.00391	0.0123	CcSEcCtD
Phenylpropanolamine—ADRB1—brain—multiple sclerosis	0.00391	0.0122	CbGeAlD
Phenylpropanolamine—Euphoric mood—Methylprednisolone—multiple sclerosis	0.0039	0.0123	CcSEcCtD
Phenylpropanolamine—ADRA1A—central nervous system—multiple sclerosis	0.00389	0.0121	CbGeAlD
Phenylpropanolamine—MAOA—central nervous system—multiple sclerosis	0.00386	0.012	CbGeAlD
Phenylpropanolamine—Dizziness—Fingolimod—multiple sclerosis	0.00382	0.012	CcSEcCtD
Phenylpropanolamine—ADRA1A—cerebellum—multiple sclerosis	0.0038	0.0119	CbGeAlD
Phenylpropanolamine—MAOA—cerebellum—multiple sclerosis	0.00377	0.0118	CbGeAlD
Phenylpropanolamine—ADRA2A—midbrain—multiple sclerosis	0.00374	0.0117	CbGeAlD
Phenylpropanolamine—ADRA2A—spinal cord—multiple sclerosis	0.00365	0.0114	CbGeAlD
Phenylpropanolamine—Euphoric mood—Betamethasone—multiple sclerosis	0.00355	0.0112	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Dexamethasone—multiple sclerosis	0.00355	0.0112	CcSEcCtD
Phenylpropanolamine—Anxiety—Cladribine—multiple sclerosis	0.0034	0.0107	CcSEcCtD
Phenylpropanolamine—Drowsiness—Mitoxantrone—multiple sclerosis	0.00337	0.0106	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Azathioprine—multiple sclerosis	0.00335	0.0105	CcSEcCtD
Phenylpropanolamine—SLC6A2—brain—multiple sclerosis	0.00332	0.0104	CbGeAlD
Phenylpropanolamine—Confusional state—Cladribine—multiple sclerosis	0.0033	0.0104	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Methylprednisolone—multiple sclerosis	0.00322	0.0101	CcSEcCtD
Phenylpropanolamine—Tachycardia—Cladribine—multiple sclerosis	0.00319	0.0101	CcSEcCtD
Phenylpropanolamine—Irritability—Methylprednisolone—multiple sclerosis	0.00315	0.0099	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Prednisone—multiple sclerosis	0.00309	0.00972	CcSEcCtD
Phenylpropanolamine—ADRA1A—brain—multiple sclerosis	0.00309	0.00964	CbGeAlD
Phenylpropanolamine—ADRA2A—nervous system—multiple sclerosis	0.00307	0.00959	CbGeAlD
Phenylpropanolamine—MAOA—brain—multiple sclerosis	0.00306	0.00955	CbGeAlD
Phenylpropanolamine—Hypotension—Cladribine—multiple sclerosis	0.00306	0.00963	CcSEcCtD
Phenylpropanolamine—Insomnia—Cladribine—multiple sclerosis	0.00296	0.00932	CcSEcCtD
Phenylpropanolamine—ADRA2A—central nervous system—multiple sclerosis	0.00296	0.00923	CbGeAlD
Phenylpropanolamine—Psychotic disorder—Dexamethasone—multiple sclerosis	0.00293	0.00921	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Betamethasone—multiple sclerosis	0.00293	0.00921	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Cladribine—multiple sclerosis	0.00292	0.00919	CcSEcCtD
Phenylpropanolamine—Somnolence—Cladribine—multiple sclerosis	0.00291	0.00916	CcSEcCtD
Phenylpropanolamine—ADRA2A—cerebellum—multiple sclerosis	0.00289	0.00902	CbGeAlD
Phenylpropanolamine—Irritability—Betamethasone—multiple sclerosis	0.00286	0.009	CcSEcCtD
Phenylpropanolamine—Irritability—Dexamethasone—multiple sclerosis	0.00286	0.009	CcSEcCtD
Phenylpropanolamine—Constipation—Cladribine—multiple sclerosis	0.0028	0.00881	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Mitoxantrone—multiple sclerosis	0.00271	0.00852	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Cladribine—multiple sclerosis	0.0027	0.00849	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Prednisone—multiple sclerosis	0.00255	0.00802	CcSEcCtD
Phenylpropanolamine—Irritability—Prednisone—multiple sclerosis	0.00249	0.00784	CcSEcCtD
Phenylpropanolamine—Hypotension—Azathioprine—multiple sclerosis	0.00249	0.00783	CcSEcCtD
Phenylpropanolamine—Vision blurred—Mitoxantrone—multiple sclerosis	0.00248	0.00782	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Cladribine—multiple sclerosis	0.00241	0.00759	CcSEcCtD
Phenylpropanolamine—ADRA2A—brain—multiple sclerosis	0.00235	0.00733	CbGeAlD
Phenylpropanolamine—Hallucination—Methylprednisolone—multiple sclerosis	0.00227	0.00714	CcSEcCtD
Phenylpropanolamine—Anxiety—Mitoxantrone—multiple sclerosis	0.00224	0.00704	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Prednisolone—multiple sclerosis	0.00222	0.00699	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Azathioprine—multiple sclerosis	0.00219	0.0069	CcSEcCtD
Phenylpropanolamine—Confusional state—Mitoxantrone—multiple sclerosis	0.00217	0.00683	CcSEcCtD
Phenylpropanolamine—Dizziness—Cladribine—multiple sclerosis	0.00216	0.00681	CcSEcCtD
Phenylpropanolamine—Tachycardia—Mitoxantrone—multiple sclerosis	0.0021	0.00661	CcSEcCtD
Phenylpropanolamine—Irritability—Methotrexate—multiple sclerosis	0.00208	0.00655	CcSEcCtD
Phenylpropanolamine—Vomiting—Cladribine—multiple sclerosis	0.00208	0.00655	CcSEcCtD
Phenylpropanolamine—Rash—Cladribine—multiple sclerosis	0.00206	0.0065	CcSEcCtD
Phenylpropanolamine—Hallucination—Betamethasone—multiple sclerosis	0.00206	0.00649	CcSEcCtD
Phenylpropanolamine—Hallucination—Dexamethasone—multiple sclerosis	0.00206	0.00649	CcSEcCtD
Phenylpropanolamine—Dermatitis—Cladribine—multiple sclerosis	0.00206	0.00649	CcSEcCtD
Phenylpropanolamine—Ataxia—Methotrexate—multiple sclerosis	0.00205	0.00646	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Triamcinolone—multiple sclerosis	0.00204	0.00643	CcSEcCtD
Phenylpropanolamine—Vision blurred—Prednisolone—multiple sclerosis	0.00204	0.00642	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Methylprednisolone—multiple sclerosis	0.00204	0.00641	CcSEcCtD
Phenylpropanolamine—Hypotension—Mitoxantrone—multiple sclerosis	0.00201	0.00633	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Azathioprine—multiple sclerosis	0.00196	0.00617	CcSEcCtD
Phenylpropanolamine—Nausea—Cladribine—multiple sclerosis	0.00194	0.00612	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Mitoxantrone—multiple sclerosis	0.00192	0.00604	CcSEcCtD
Phenylpropanolamine—Somnolence—Mitoxantrone—multiple sclerosis	0.00191	0.00602	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Betamethasone—multiple sclerosis	0.00185	0.00583	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Dexamethasone—multiple sclerosis	0.00185	0.00583	CcSEcCtD
Phenylpropanolamine—Constipation—Mitoxantrone—multiple sclerosis	0.00184	0.00579	CcSEcCtD
Phenylpropanolamine—Hallucination—Prednisone—multiple sclerosis	0.0018	0.00566	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.00177	0.00558	CcSEcCtD
Phenylpropanolamine—Dizziness—Azathioprine—multiple sclerosis	0.00176	0.00554	CcSEcCtD
Phenylpropanolamine—Tachycardia—Prednisolone—multiple sclerosis	0.00172	0.00542	CcSEcCtD
Phenylpropanolamine—Vomiting—Azathioprine—multiple sclerosis	0.00169	0.00533	CcSEcCtD
Phenylpropanolamine—Anxiety—Methylprednisolone—multiple sclerosis	0.00168	0.0053	CcSEcCtD
Phenylpropanolamine—Drowsiness—Methotrexate—multiple sclerosis	0.00168	0.00529	CcSEcCtD
Phenylpropanolamine—Rash—Azathioprine—multiple sclerosis	0.00168	0.00528	CcSEcCtD
Phenylpropanolamine—Dermatitis—Azathioprine—multiple sclerosis	0.00168	0.00528	CcSEcCtD
Phenylpropanolamine—Flushing—Prednisone—multiple sclerosis	0.00168	0.00527	CcSEcCtD
Phenylpropanolamine—Confusional state—Methylprednisolone—multiple sclerosis	0.00163	0.00514	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Prednisone—multiple sclerosis	0.00161	0.00508	CcSEcCtD
Phenylpropanolamine—Insomnia—Prednisolone—multiple sclerosis	0.0016	0.00503	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00159	0.00499	CcSEcCtD
Phenylpropanolamine—Tachycardia—Triamcinolone—multiple sclerosis	0.00158	0.00499	CcSEcCtD
Phenylpropanolamine—Nausea—Azathioprine—multiple sclerosis	0.00158	0.00498	CcSEcCtD
Phenylpropanolamine—Tachycardia—Methylprednisolone—multiple sclerosis	0.00158	0.00498	CcSEcCtD
Phenylpropanolamine—Anxiety—Dexamethasone—multiple sclerosis	0.00153	0.00482	CcSEcCtD
Phenylpropanolamine—Anxiety—Betamethasone—multiple sclerosis	0.00153	0.00482	CcSEcCtD
Phenylpropanolamine—Hypotension—Methylprednisolone—multiple sclerosis	0.00151	0.00476	CcSEcCtD
Phenylpropanolamine—Vision blurred—Prednisone—multiple sclerosis	0.00148	0.00466	CcSEcCtD
Phenylpropanolamine—Insomnia—Triamcinolone—multiple sclerosis	0.00147	0.00462	CcSEcCtD
Phenylpropanolamine—Insomnia—Methylprednisolone—multiple sclerosis	0.00146	0.00461	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Prednisolone—multiple sclerosis	0.00145	0.00458	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Triamcinolone—multiple sclerosis	0.00145	0.00456	CcSEcCtD
Phenylpropanolamine—Agitation—Prednisone—multiple sclerosis	0.00144	0.00455	CcSEcCtD
Phenylpropanolamine—Tachycardia—Dexamethasone—multiple sclerosis	0.00144	0.00453	CcSEcCtD
Phenylpropanolamine—Tachycardia—Betamethasone—multiple sclerosis	0.00144	0.00453	CcSEcCtD
Phenylpropanolamine—Hypotension—Dexamethasone—multiple sclerosis	0.00138	0.00433	CcSEcCtD
Phenylpropanolamine—Hypotension—Betamethasone—multiple sclerosis	0.00138	0.00433	CcSEcCtD
Phenylpropanolamine—Vomiting—Mitoxantrone—multiple sclerosis	0.00137	0.00431	CcSEcCtD
Phenylpropanolamine—Rash—Mitoxantrone—multiple sclerosis	0.00136	0.00427	CcSEcCtD
Phenylpropanolamine—Dermatitis—Mitoxantrone—multiple sclerosis	0.00136	0.00427	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.00134	0.00421	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.00133	0.0042	CcSEcCtD
Phenylpropanolamine—Anxiety—Prednisone—multiple sclerosis	0.00133	0.0042	CcSEcCtD
Phenylpropanolamine—Insomnia—Betamethasone—multiple sclerosis	0.00133	0.00419	CcSEcCtD
Phenylpropanolamine—Insomnia—Dexamethasone—multiple sclerosis	0.00133	0.00419	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Prednisolone—multiple sclerosis	0.0013	0.00409	CcSEcCtD
Phenylpropanolamine—Nausea—Mitoxantrone—multiple sclerosis	0.00128	0.00402	CcSEcCtD
Phenylpropanolamine—Tachycardia—Prednisone—multiple sclerosis	0.00125	0.00394	CcSEcCtD
Phenylpropanolamine—Vision blurred—Methotrexate—multiple sclerosis	0.00124	0.0039	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.00121	0.00382	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Betamethasone—multiple sclerosis	0.00121	0.00382	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Triamcinolone—multiple sclerosis	0.0012	0.00376	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.00119	0.00376	CcSEcCtD
Phenylpropanolamine—Dizziness—Prednisolone—multiple sclerosis	0.00117	0.00367	CcSEcCtD
Phenylpropanolamine—Insomnia—Prednisone—multiple sclerosis	0.00116	0.00365	CcSEcCtD
Phenylpropanolamine—Rash—Prednisolone—multiple sclerosis	0.00111	0.0035	CcSEcCtD
Phenylpropanolamine—Dermatitis—Prednisolone—multiple sclerosis	0.00111	0.0035	CcSEcCtD
Phenylpropanolamine—Constipation—Prednisone—multiple sclerosis	0.0011	0.00345	CcSEcCtD
Phenylpropanolamine—Confusional state—Methotrexate—multiple sclerosis	0.00108	0.0034	CcSEcCtD
Phenylpropanolamine—Dizziness—Triamcinolone—multiple sclerosis	0.00107	0.00338	CcSEcCtD
Phenylpropanolamine—Dizziness—Methylprednisolone—multiple sclerosis	0.00107	0.00337	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Prednisone—multiple sclerosis	0.00106	0.00333	CcSEcCtD
Phenylpropanolamine—Nausea—Prednisolone—multiple sclerosis	0.00105	0.0033	CcSEcCtD
Phenylpropanolamine—Vomiting—Triamcinolone—multiple sclerosis	0.00103	0.00325	CcSEcCtD
Phenylpropanolamine—Vomiting—Methylprednisolone—multiple sclerosis	0.00103	0.00324	CcSEcCtD
Phenylpropanolamine—Rash—Triamcinolone—multiple sclerosis	0.00102	0.00322	CcSEcCtD
Phenylpropanolamine—Dermatitis—Triamcinolone—multiple sclerosis	0.00102	0.00322	CcSEcCtD
Phenylpropanolamine—Rash—Methylprednisolone—multiple sclerosis	0.00102	0.00321	CcSEcCtD
Phenylpropanolamine—Dermatitis—Methylprednisolone—multiple sclerosis	0.00102	0.00321	CcSEcCtD
Phenylpropanolamine—Hypotension—Methotrexate—multiple sclerosis	0.001	0.00315	CcSEcCtD
Phenylpropanolamine—Dizziness—Betamethasone—multiple sclerosis	0.000974	0.00307	CcSEcCtD
Phenylpropanolamine—Dizziness—Dexamethasone—multiple sclerosis	0.000974	0.00307	CcSEcCtD
Phenylpropanolamine—Insomnia—Methotrexate—multiple sclerosis	0.00097	0.00305	CcSEcCtD
Phenylpropanolamine—Nausea—Triamcinolone—multiple sclerosis	0.000964	0.00304	CcSEcCtD
Phenylpropanolamine—Nausea—Methylprednisolone—multiple sclerosis	0.000962	0.00303	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Methotrexate—multiple sclerosis	0.000956	0.00301	CcSEcCtD
Phenylpropanolamine—Somnolence—Methotrexate—multiple sclerosis	0.000953	0.003	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Prednisone—multiple sclerosis	0.000945	0.00298	CcSEcCtD
Phenylpropanolamine—Vomiting—Betamethasone—multiple sclerosis	0.000936	0.00295	CcSEcCtD
Phenylpropanolamine—Vomiting—Dexamethasone—multiple sclerosis	0.000936	0.00295	CcSEcCtD
Phenylpropanolamine—Rash—Betamethasone—multiple sclerosis	0.000929	0.00292	CcSEcCtD
Phenylpropanolamine—Rash—Dexamethasone—multiple sclerosis	0.000929	0.00292	CcSEcCtD
Phenylpropanolamine—Dermatitis—Betamethasone—multiple sclerosis	0.000928	0.00292	CcSEcCtD
Phenylpropanolamine—Dermatitis—Dexamethasone—multiple sclerosis	0.000928	0.00292	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Methotrexate—multiple sclerosis	0.000883	0.00278	CcSEcCtD
Phenylpropanolamine—Nausea—Betamethasone—multiple sclerosis	0.000875	0.00275	CcSEcCtD
Phenylpropanolamine—Nausea—Dexamethasone—multiple sclerosis	0.000875	0.00275	CcSEcCtD
Phenylpropanolamine—Dizziness—Prednisone—multiple sclerosis	0.000848	0.00267	CcSEcCtD
Phenylpropanolamine—Vomiting—Prednisone—multiple sclerosis	0.000816	0.00257	CcSEcCtD
Phenylpropanolamine—Rash—Prednisone—multiple sclerosis	0.000809	0.00255	CcSEcCtD
Phenylpropanolamine—Dermatitis—Prednisone—multiple sclerosis	0.000808	0.00254	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Methotrexate—multiple sclerosis	0.00079	0.00249	CcSEcCtD
Phenylpropanolamine—Nausea—Prednisone—multiple sclerosis	0.000762	0.0024	CcSEcCtD
Phenylpropanolamine—Dizziness—Methotrexate—multiple sclerosis	0.000709	0.00223	CcSEcCtD
Phenylpropanolamine—Vomiting—Methotrexate—multiple sclerosis	0.000682	0.00215	CcSEcCtD
Phenylpropanolamine—Rash—Methotrexate—multiple sclerosis	0.000676	0.00213	CcSEcCtD
Phenylpropanolamine—Dermatitis—Methotrexate—multiple sclerosis	0.000675	0.00213	CcSEcCtD
Phenylpropanolamine—Nausea—Methotrexate—multiple sclerosis	0.000637	0.002	CcSEcCtD
Phenylpropanolamine—ADRB1—Signaling by GPCR—CXCL10—multiple sclerosis	0.00019	0.000563	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—CCR2—multiple sclerosis	0.00019	0.000561	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—CNR1—multiple sclerosis	0.000188	0.000557	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	0.000187	0.000554	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CXCL10—multiple sclerosis	0.000186	0.000551	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—GPR65—multiple sclerosis	0.000186	0.00055	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CCR2—multiple sclerosis	0.000185	0.000548	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PTGER4—multiple sclerosis	0.000183	0.000542	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	0.000182	0.00054	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—CCL5—multiple sclerosis	0.000182	0.000539	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RGS1—multiple sclerosis	0.000182	0.000539	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—POMC—multiple sclerosis	0.000182	0.000538	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—CCR5—multiple sclerosis	0.000181	0.000535	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—CCL5—multiple sclerosis	0.00018	0.000534	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000178	0.000527	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—CCL2—multiple sclerosis	0.000178	0.000527	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—BCHE—multiple sclerosis	0.000177	0.000525	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CXCR3—multiple sclerosis	0.000177	0.000524	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—CCL5—multiple sclerosis	0.000176	0.000522	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—CNR1—multiple sclerosis	0.000175	0.000518	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—GPR65—multiple sclerosis	0.000173	0.000511	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CCR2—multiple sclerosis	0.000172	0.00051	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CNR1—multiple sclerosis	0.000171	0.000506	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CXCL13—multiple sclerosis	0.00017	0.000503	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCR1—multiple sclerosis	0.00017	0.000503	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000169	0.000502	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	0.000169	0.0005	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—POMC—multiple sclerosis	0.000169	0.0005	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCL3—multiple sclerosis	0.000166	0.000492	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—ALB—multiple sclerosis	0.000166	0.000491	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	0.000166	0.000491	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—CCL2—multiple sclerosis	0.000165	0.000489	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—CCR5—multiple sclerosis	0.000164	0.000486	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—CCL5—multiple sclerosis	0.000164	0.000485	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—CCR5—multiple sclerosis	0.000162	0.000481	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL2RA—multiple sclerosis	0.000162	0.000479	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CCL5—multiple sclerosis	0.00016	0.000474	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTGER4—multiple sclerosis	0.00016	0.000474	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—IL2RA—multiple sclerosis	0.00016	0.000474	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—CCR5—multiple sclerosis	0.000159	0.000471	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CNR1—multiple sclerosis	0.000159	0.00047	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CXCL13—multiple sclerosis	0.000158	0.000467	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCR1—multiple sclerosis	0.000158	0.000467	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PGR—multiple sclerosis	0.000158	0.000467	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000157	0.000466	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000157	0.000464	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CXCR3—multiple sclerosis	0.000155	0.000458	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CXCL10—multiple sclerosis	0.000154	0.000456	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CD28—multiple sclerosis	0.000153	0.000454	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCR2—multiple sclerosis	0.00015	0.000445	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	0.00015	0.000445	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	0.00015	0.000445	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCL3—multiple sclerosis	0.00015	0.000443	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—CCR5—multiple sclerosis	0.000148	0.000437	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000147	0.000435	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCL3—multiple sclerosis	0.000146	0.000433	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—CCL5—multiple sclerosis	0.000146	0.000432	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL2RA—multiple sclerosis	0.000145	0.00043	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CCR5—multiple sclerosis	0.000144	0.000427	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTGER4—multiple sclerosis	0.000144	0.000426	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CXCL10—multiple sclerosis	0.000143	0.000423	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL2RA—multiple sclerosis	0.000142	0.000421	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PGR—multiple sclerosis	0.000142	0.00042	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—POMC—multiple sclerosis	0.000141	0.000418	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTGER4—multiple sclerosis	0.000141	0.000417	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	0.00014	0.000415	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CXCR3—multiple sclerosis	0.000139	0.000412	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CNR1—multiple sclerosis	0.000139	0.000411	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PGR—multiple sclerosis	0.000139	0.000411	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CD28—multiple sclerosis	0.000138	0.000408	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—ALB—multiple sclerosis	0.000138	0.000408	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GPC5—multiple sclerosis	0.000137	0.000407	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CXCR3—multiple sclerosis	0.000136	0.000403	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—CCL5—multiple sclerosis	0.000136	0.000401	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCR2—multiple sclerosis	0.000135	0.0004	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CD28—multiple sclerosis	0.000135	0.000399	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CCL5—multiple sclerosis	0.000132	0.000392	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCR2—multiple sclerosis	0.000132	0.000392	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—CCR5—multiple sclerosis	0.000131	0.000389	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—IL2RA—multiple sclerosis	0.00013	0.000384	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—POMC—multiple sclerosis	0.000128	0.00038	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—POMC—multiple sclerosis	0.000127	0.000376	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—CCL2—multiple sclerosis	0.000125	0.000372	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CXCL10—multiple sclerosis	0.000125	0.00037	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CNR1—multiple sclerosis	0.000125	0.00037	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—POMC—multiple sclerosis	0.000124	0.000368	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CCL5—multiple sclerosis	0.000123	0.000364	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—CCR5—multiple sclerosis	0.000122	0.000362	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CNR1—multiple sclerosis	0.000122	0.000361	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCL3—multiple sclerosis	0.000121	0.000358	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—IL2RA—multiple sclerosis	0.00012	0.000356	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CCR5—multiple sclerosis	0.000119	0.000353	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—BCHE—multiple sclerosis	0.000118	0.000351	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL2RA—multiple sclerosis	0.000118	0.000348	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTGER4—multiple sclerosis	0.000116	0.000345	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—POMC—multiple sclerosis	0.000115	0.000341	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PGR—multiple sclerosis	0.000115	0.00034	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—TYK2—multiple sclerosis	0.000114	0.000337	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—RRM1—multiple sclerosis	0.000114	0.000337	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—CCL2—multiple sclerosis	0.000113	0.000334	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—POMC—multiple sclerosis	0.000113	0.000334	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CXCR3—multiple sclerosis	0.000112	0.000333	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCL3—multiple sclerosis	0.000112	0.000333	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CXCL10—multiple sclerosis	0.000112	0.000333	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—IL2—multiple sclerosis	0.000112	0.000331	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CD28—multiple sclerosis	0.000111	0.00033	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CCR5—multiple sclerosis	0.000111	0.000328	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CCL2—multiple sclerosis	0.00011	0.000327	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CXCL10—multiple sclerosis	0.00011	0.000325	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCR2—multiple sclerosis	0.000109	0.000324	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL2RA—multiple sclerosis	0.000109	0.000324	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CD86—multiple sclerosis	0.000109	0.000324	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTGER4—multiple sclerosis	0.000108	0.00032	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCL5—multiple sclerosis	0.000108	0.000319	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—APOE—multiple sclerosis	0.000107	0.000316	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PGR—multiple sclerosis	0.000107	0.000316	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CXCR3—multiple sclerosis	0.000105	0.000309	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—IL2—multiple sclerosis	0.000104	0.000309	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CD28—multiple sclerosis	0.000104	0.000307	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—POMC—multiple sclerosis	0.000103	0.000304	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—TYK2—multiple sclerosis	0.000102	0.000303	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCR2—multiple sclerosis	0.000102	0.000301	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CNR1—multiple sclerosis	0.000101	0.000299	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—TYK2—multiple sclerosis	0.0001	0.000297	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SPP1—multiple sclerosis	9.97e-05	0.000295	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CD86—multiple sclerosis	9.83e-05	0.000291	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCR5—multiple sclerosis	9.69e-05	0.000287	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCL5—multiple sclerosis	9.67e-05	0.000286	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CD86—multiple sclerosis	9.61e-05	0.000285	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL2RA—multiple sclerosis	9.55e-05	0.000283	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—POMC—multiple sclerosis	9.55e-05	0.000283	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL2—multiple sclerosis	9.48e-05	0.000281	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCL5—multiple sclerosis	9.46e-05	0.00028	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—IL2—multiple sclerosis	9.39e-05	0.000278	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CNR1—multiple sclerosis	9.38e-05	0.000278	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—POMC—multiple sclerosis	9.33e-05	0.000276	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—IL2—multiple sclerosis	9.18e-05	0.000272	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—POMC—multiple sclerosis	9.17e-05	0.000271	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CCL2—multiple sclerosis	9.13e-05	0.00027	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CXCL10—multiple sclerosis	9.09e-05	0.000269	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SPP1—multiple sclerosis	8.96e-05	0.000265	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	8.84e-05	0.000262	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—APOE—multiple sclerosis	8.82e-05	0.000261	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SPP1—multiple sclerosis	8.76e-05	0.000259	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCR5—multiple sclerosis	8.72e-05	0.000258	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TGFB1—multiple sclerosis	8.71e-05	0.000258	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—POMC—multiple sclerosis	8.67e-05	0.000257	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL2RA—multiple sclerosis	8.59e-05	0.000254	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—MAPK1—multiple sclerosis	8.54e-05	0.000253	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCR5—multiple sclerosis	8.53e-05	0.000252	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL2—multiple sclerosis	8.52e-05	0.000252	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CCL2—multiple sclerosis	8.48e-05	0.000251	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CXCL10—multiple sclerosis	8.45e-05	0.00025	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL2RA—multiple sclerosis	8.4e-05	0.000249	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ALB—multiple sclerosis	8.36e-05	0.000247	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL2—multiple sclerosis	8.34e-05	0.000247	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—TYK2—multiple sclerosis	8.29e-05	0.000245	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CD80—multiple sclerosis	7.97e-05	0.000236	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CD86—multiple sclerosis	7.95e-05	0.000235	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—APOE—multiple sclerosis	7.93e-05	0.000235	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCL5—multiple sclerosis	7.83e-05	0.000232	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—APOE—multiple sclerosis	7.76e-05	0.00023	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—TYK2—multiple sclerosis	7.7e-05	0.000228	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—IL2—multiple sclerosis	7.59e-05	0.000225	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.59e-05	0.000225	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—POMC—multiple sclerosis	7.58e-05	0.000224	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCL2—multiple sclerosis	7.41e-05	0.000219	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CD86—multiple sclerosis	7.39e-05	0.000219	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCL5—multiple sclerosis	7.27e-05	0.000215	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—MAPK1—multiple sclerosis	7.25e-05	0.000215	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SPP1—multiple sclerosis	7.25e-05	0.000215	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CD80—multiple sclerosis	7.17e-05	0.000212	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—APOE—multiple sclerosis	7.13e-05	0.000211	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—IL2—multiple sclerosis	7.06e-05	0.000209	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCR5—multiple sclerosis	7.05e-05	0.000209	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CD80—multiple sclerosis	7.01e-05	0.000208	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL2RA—multiple sclerosis	6.95e-05	0.000206	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.92e-05	0.000205	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL2—multiple sclerosis	6.9e-05	0.000204	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—POMC—multiple sclerosis	6.81e-05	0.000202	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SPP1—multiple sclerosis	6.74e-05	0.000199	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TYK2—multiple sclerosis	6.73e-05	0.000199	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCL2—multiple sclerosis	6.66e-05	0.000197	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—POMC—multiple sclerosis	6.66e-05	0.000197	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCR5—multiple sclerosis	6.55e-05	0.000194	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—BCHE—multiple sclerosis	6.54e-05	0.000194	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—MAPK1—multiple sclerosis	6.52e-05	0.000193	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCL2—multiple sclerosis	6.52e-05	0.000193	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL2RA—multiple sclerosis	6.46e-05	0.000191	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOE—multiple sclerosis	6.42e-05	0.00019	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL2—multiple sclerosis	6.41e-05	0.00019	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—MAPK1—multiple sclerosis	6.38e-05	0.000189	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—POMC—multiple sclerosis	6.12e-05	0.000181	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TYK2—multiple sclerosis	6.05e-05	0.000179	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOE—multiple sclerosis	5.96e-05	0.000176	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TYK2—multiple sclerosis	5.92e-05	0.000175	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CD80—multiple sclerosis	5.8e-05	0.000172	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL2—multiple sclerosis	5.6e-05	0.000166	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ALB—multiple sclerosis	5.58e-05	0.000165	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL6—multiple sclerosis	5.57e-05	0.000165	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—POMC—multiple sclerosis	5.51e-05	0.000163	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCL2—multiple sclerosis	5.39e-05	0.00016	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CD80—multiple sclerosis	5.39e-05	0.00016	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MMP9—multiple sclerosis	5.3e-05	0.000157	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—MAPK1—multiple sclerosis	5.28e-05	0.000156	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—POMC—multiple sclerosis	5.12e-05	0.000152	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL2—multiple sclerosis	5.04e-05	0.000149	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL6—multiple sclerosis	5.01e-05	0.000148	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCL2—multiple sclerosis	5.01e-05	0.000148	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL2—multiple sclerosis	4.93e-05	0.000146	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—MAPK1—multiple sclerosis	4.9e-05	0.000145	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL6—multiple sclerosis	4.9e-05	0.000145	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TYK2—multiple sclerosis	4.9e-05	0.000145	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MMP9—multiple sclerosis	4.77e-05	0.000141	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—STAT3—multiple sclerosis	4.71e-05	0.00014	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MMP9—multiple sclerosis	4.66e-05	0.000138	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TYK2—multiple sclerosis	4.55e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MYC—multiple sclerosis	4.38e-05	0.00013	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TGFB1—multiple sclerosis	4.37e-05	0.000129	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MAPK1—multiple sclerosis	4.28e-05	0.000127	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—STAT3—multiple sclerosis	4.24e-05	0.000125	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—STAT3—multiple sclerosis	4.14e-05	0.000123	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL2—multiple sclerosis	4.07e-05	0.000121	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6—multiple sclerosis	4.05e-05	0.00012	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MYC—multiple sclerosis	3.94e-05	0.000117	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOE—multiple sclerosis	3.94e-05	0.000117	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TGFB1—multiple sclerosis	3.93e-05	0.000116	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MMP9—multiple sclerosis	3.86e-05	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAPK1—multiple sclerosis	3.85e-05	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MYC—multiple sclerosis	3.85e-05	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TGFB1—multiple sclerosis	3.84e-05	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL2—multiple sclerosis	3.79e-05	0.000112	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAPK1—multiple sclerosis	3.77e-05	0.000112	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6—multiple sclerosis	3.77e-05	0.000112	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MMP9—multiple sclerosis	3.58e-05	0.000106	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—STAT3—multiple sclerosis	3.43e-05	0.000102	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—POMC—multiple sclerosis	3.38e-05	0.0001	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6—multiple sclerosis	3.29e-05	9.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MYC—multiple sclerosis	3.19e-05	9.43e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—STAT3—multiple sclerosis	3.19e-05	9.43e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TGFB1—multiple sclerosis	3.18e-05	9.41e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK1—multiple sclerosis	3.12e-05	9.23e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ALB—multiple sclerosis	3.08e-05	9.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MYC—multiple sclerosis	2.96e-05	8.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6—multiple sclerosis	2.96e-05	8.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TGFB1—multiple sclerosis	2.95e-05	8.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK1—multiple sclerosis	2.9e-05	8.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6—multiple sclerosis	2.9e-05	8.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6—multiple sclerosis	2.39e-05	7.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6—multiple sclerosis	2.23e-05	6.59e-05	CbGpPWpGaD
